A 62-year-old male patient received two doses of Pembrolizumab (200 mg, q3w) to treat melanoma until he was admitted to our cardio-oncology unit due to elevations of hs-troponinT (hsTnT) (39 pg/ml) and NT-proBNP (2,900 ng/l). The gene discussed is NPPB; the disease is melanoma.